X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ACTAVIS (US) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   ACTAVIS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
ACTAVIS
Dec-14
DR. REDDYS LAB/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs3,39718,553-   
Low Rs2,56011,317-   
Sales per share (Unadj.) Rs856.53,340.9-  
Earnings per share (Unadj.) Rs78.0-416.9-  
Cash flow per share (Unadj.) Rs139.9306.5-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs739.87,246.3-  
Shares outstanding (eoy) m165.74265.90-   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.54.5 77.8%   
Avg P/E ratio x38.2-35.8 -106.6%  
P/CF ratio (eoy) x21.348.7 43.7%  
Price / Book Value ratio x4.02.1 195.3%  
Dividend payout %25.70-   
Avg Mkt Cap Rs m493,6323,971,215 12.4%   
No. of employees `00022.721.6 105.0%   
Total wages/salary Rs m31,0680-   
Avg. sales/employee Rs Th6,259.041,127.2 15.2%   
Avg. wages/employee Rs Th1,369.80-   
Avg. net profit/employee Rs Th569.7-5,132.2 -11.1%   
INCOME DATA
Net Sales Rs m141,961888,347 16.0%  
Other income Rs m1,715-2,217 -77.4%   
Total revenues Rs m143,676886,129 16.2%   
Gross profit Rs m24,722114,121 21.7%  
Depreciation Rs m10,266192,359 5.3%   
Interest Rs m63428,020 2.3%   
Profit before tax Rs m15,537-108,476 -14.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0-7,957 0.0%   
Tax Rs m2,965-5,577 -53.2%   
Profit after tax Rs m12,921-110,856 -11.7%  
Gross profit margin %17.412.8 135.6%  
Effective tax rate %19.15.1 371.2%   
Net profit margin %9.1-12.5 -72.9%  
BALANCE SHEET DATA
Current assets Rs m96,837468,045 20.7%   
Current liabilities Rs m84,199341,342 24.7%   
Net working cap to sales %8.914.3 62.4%  
Current ratio x1.21.4 83.9%  
Inventory Days Days7358 126.4%  
Debtors Days Days9866 147.3%  
Net fixed assets Rs m102,552108,476 94.5%   
Share capital Rs m8290-   
"Free" reserves Rs m121,7920-   
Net worth Rs m122,6211,926,791 6.4%   
Long term debt Rs m5,4491,009,676 0.5%   
Total assets Rs m218,1653,531,174 6.2%  
Interest coverage x25.5-2.9 -888.3%   
Debt to equity ratio x00.5 8.5%  
Sales to assets ratio x0.70.3 258.7%   
Return on assets %6.2-2.3 -264.9%  
Return on equity %10.5-5.8 -183.1%  
Return on capital %12.9-3.0 -428.4%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Net fx Rs m55,3150-   
CASH FLOW
From Operations Rs m21,444152,546 14.1%  
From Investments Rs m-18,404-365,255 5.0%  
From Financial Activity Rs m-3,692205,220 -1.8%  
Net Cashflow Rs m-1,144-7,488 15.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.01 Rs / USD

Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: UNICHEM LAB  STRIDES SHASUN LTD  ABBOTT INDIA  SUN PHARMA  AJANTA PHARMA  



Today's Market

Indian Indices Trade in Red; US-China Trade War Back On; IPO Buzz and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened flat and ended the day in red. The S&P BSE Midcap Index ended down by 1% while S&P BSE Small Cap Index ended down by 1.3%.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 19, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS